Show simple item record

dc.contributor.authorBacon, David J.en_US
dc.contributor.authorJambou, Ronanen_US
dc.contributor.authorFandeur, Thierryen_US
dc.contributor.authorLe Bras, Jacquesen_US
dc.contributor.authorWongsrichanalai, Chansudaen_US
dc.contributor.authorFukuda, Mark M.en_US
dc.contributor.authorRingwald, Pascalen_US
dc.contributor.authorSibley, Carol Hopkinsen_US
dc.contributor.authorKyle, Dennis E.en_US
dc.date.accessioned2010-05-06T20:05:55Z
dc.date.available2010-05-06T20:05:55Z
dc.date.issued2007en_US
dc.identifier.citationBacon D, Jambou R, Fandeur T, et al. World Antimalarial Resistance Network (WARN) II: In vitro antimalarial drug susceptibility. Malaria Journal. 2007;6(1):120.en_US
dc.identifier.other10.1186/1475-2875-6-120en_US
dc.identifier.urihttp://www.malariajournal.com/content/6/1/120en_US
dc.identifier.urihttp://hdl.handle.net/1773/15843
dc.description.abstractIntrinsic resistance of Plasmodium falciparum is clearly a major determinant of the clinical failure of antimalarial drugs. However, complex interactions between the host, the parasite and the drug obscure the ability to define parasite drug resistance in vivo. The in vitro antimalarial drug susceptibility assay determines ex-vivo growth of parasite in the presence of serial drug concentrations and, thus, eliminates host effects, such as drug metabolism and immunity. Although the sensitivity of the parasite to various antimalarials provided by such a test provides an important indicator of intrinsic parasite susceptibility, there are fundamental methodological issues that undermine comparison of in vitro susceptibility both between laboratories and within a single laboratory over time. A network of laboratories is proposed that will agree on the basic parameters of the in vitro test and associated measures of quality control. The aim of the network would be to establish baseline values of sensitivity to commonly used antimalarial agents from key regions of the world, and create a global database, linked to clinical, molecular and pharmacology databases, to support active surveillance to monitor temporal trends in parasite susceptibility. Such a network would facilitate the rapid detection of strains with novel antimalarial resistance profiles and investigate suitable alternative treatments with retained efficacy.en_US
dc.description.sponsorshipSome of this work was supported by funds provided by the Department of Defense-Global Emerging Infectious System (DoD-GEIS) under the unit number 847705.82000.256B, B0016.en_US
dc.language.isoen_USen_US
dc.titleWorld Antimalarial Resistance Network (WARN) II: In vitro antimalarial drug susceptibilityen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record